BRISBANE, Calif., Sept. 19, 2023 Annexon, Inc. , a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated.
Shifting Paradigms in Neovascular Retinal Disease: Novel Ways to Address Anti-VEGF Injection Burden and Insufficient Response healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Great Debates in Neovascular Retinal Disease: What Do the Data Really Tell Us About Treatment? healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Alerce Investment Management L.P. increased its holdings in Annexon, Inc. (NASDAQ:ANNX – Free Report) by 60.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,056,024 shares of the company’s stock after purchasing an additional 2,647,058 shares during the quarter. Annexon accounts for about 35.9% […]
Alerce Investment Management L.P. raised its stake in Annexon, Inc. (NASDAQ:ANNX – Free Report) by 60.0% during the 1st quarter, HoldingsChannel reports. The firm owned 7,056,024 shares of the company’s stock after acquiring an additional 2,647,058 shares during the quarter. Annexon accounts for about 35.9% of Alerce Investment Management L.P.’s portfolio, making the stock its […]